Targeting the Diabetic Chaperome to Improve Peripheral Neuropathy

Area of Science:

• Molecular biology and biochemistry
• Cellular stress response mechanisms
• Pharmacology and drug discovery

Background:

• The chaperome, including Heat Shock Protein 90 (Hsp90), regulates protein folding, refolding, and degradation.
• Hsp90 is crucial for stabilizing oncoproteins, supporting cancer cell survival.
• Small molecule Hsp90 inhibitors are investigated as anti-cancer therapeutics due to their selective targeting of tumor cell complexes.

Purpose of the Study:

• To explore the concept of a disease-specific 'stress chaperome'.
• To investigate the therapeutic potential of targeting Hsp90 in disease contexts beyond cancer, such as diabetic neuropathy.
• To discuss the implications of targeting the 'diabetic chaperome' for treating diabetes and its complications.

Main Methods:

• Review and synthesis of existing research on Hsp90 function and inhibition.
• Analysis of Hsp90's role in oncogenic transformation and cellular stress.
• Examination of Hsp90 modulation effects in models of diabetic peripheral neuropathy.

Main Results:

• Hsp90 inhibitors show selectivity for oncogenic Hsp90 complexes in tumor cells.
• Disease states may induce a functionally distinct 'stress chaperome'.
• Modulating Hsp90 demonstrated clinical benefits in diabetic peripheral neuropathy, with minimal effect in non-diabetic nerves.

Conclusions:

• The chaperome, particularly Hsp90, presents a druggable target for various diseases.
• Disease-specific chaperome states, like the 'diabetic chaperome', can be exploited for targeted therapies.
• Targeting the 'diabetic chaperome' holds promise for treating diabetes and its associated complications.